Grifols SA ADR GRFS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.30
- Day Range
- $7.24–7.36
- 52-Week Range
- $6.96–10.23
- Bid/Ask
- $7.03 / $8.08
- Shares Outstanding
- 680.58M
- Market Cap
- $4.98B
- Volume/Avg
- 390,350 / 627,528
Key Statistics
- Price/Earnings (Normalized)
- 9.43
- Price/Sales
- 0.58
- Dividend Yield (Trailing)
- 1.45%
- Dividend Yield (Forward)
- 1.45%
- Dividend Payment Schedule
- Jul
- Total Yield
- 1.59%
Company Profile
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 25,247
- Website
- https://www.grifols.com
Valuation
|
Metric
|
GRFS
|
|---|---|
Price/Earnings (Normalized) | 9.43 |
Price/Book Value | 0.78 |
Price/Sales | 0.58 |
Price/Cash Flow | 3.66 |
Price/Earnings
GRFS
Financial Strength
|
Metric
|
GRFS
|
|---|---|
Quick Ratio | 0.77 |
Current Ratio | 2.37 |
Interest Coverage | 1.88 |
Quick Ratio
GRFS
Profitability
|
Metric
|
GRFS
|
|---|---|
Return on Assets (Normalized) | 2.73% |
Return on Equity (Normalized) | 10.19% |
Return on Invested Capital (Normalized) | 5.24% |
Return on Assets
GRFS
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|N@rq>Dkc | LOCK|%z | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|yxpwJZ | LOCK|!m | $617B | |||
| AbbVie Inc
ABBV
| LOCK|CW>#Y^ | LOCK|WP> | $464B | |||
| Merck & Co Inc
MRK
| LOCK|Xb>Lh! | LOCK|!j | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|nJT>%LV | LOCK|v% | $333B | |||
| Novartis AG ADR
NVS
| LOCK|!rQS&^C< | LOCK|!z | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|R&Rh<<& | LOCK|B!! | $248B | |||
| Amgen Inc
AMGN
| LOCK|#%<rn&& | LOCK|CL% | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|fr&thXN | LOCK|lq | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|>^F!w#< | LOCK|ft | $165B |
United States